ARTICLE | Clinical News
Verrica to submit NDA for contagious skin disease therapy
January 4, 2019 5:15 AM UTC
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) plans to submit an NDA to FDA next half for VP-102 to treat molluscum contagiosum after the compound met the primary endpoints in the identical Phase III CAMP-1 and CAMP-2 trials.
There are no FDA approved treatments for molluscum contagiosum, a highly contagious skin disease that is caused by a pox virus and primarily affects children. Verrica said the disease affects an estimated 6 million people in the U.S...
BCIQ Company Profiles